2017-11-06T08:07:18-06:00 2016-12-31 BDO USA LLP 8401 GREENSBORO DRIVE 800 MCLEAN VA 22102 990 2016-01-01 311667995 CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY % ERIN HULTMAN CONQ 5714831700 2318 MILL ROAD Suite 800 ALEXANDRIA VA 22314 ERIN HULTMAN CFO 2017-11-03 true Marc Berger P01871563 7038930600 72.190.123.86 54621820173105000002 2017-11-06 P 8833E1248867A9120A21E9498311F297C4228B1B 8833E1248867A9120A21E9498311F297C4228B1B 2016 2021-01-29 14:40:06Z CLIFFORD HUDIS MD 2318 MILL ROAD800 ALEXANDRIA VA 22314 37768298 false X WWW.CONQUER.ORG X 1999 VA CONQUERING CANCER WORLDWIDE BY FUNDING BREAKTHROUGH RESEARCH AND SHARING CUTTING-EDGE KNOWLEDGE. CCF'S VISION IS A WORLD FREE FROM THE FEAR OF CANCER. 15 14 0 145 0 29974390 23158842 0 0 564718 1416114 0 0 30539108 24574956 20564016 18319463 0 0 0 0 0 0 4314097 9507345 8926411 30071361 27245874 467747 -2670918 63169045 60197895 5277220 4678434 57891825 55519461 X The Conquer Cancer Foundation (CCF) was founded by the foremost cancer doctors of the American Society of Clinical Oncology (ASCO) to seek dramatic advances in the prevention, treatment, and cures of all types of cancer. ASCO was created in 1964 by seven cancer physicians with a single purpose: to improve the care of people with cancer. ASCO has grown from its original seven members to more than 40,000 today representing over 120 countries. As its affiliate organization, the Conquer Cancer Foundation helps support ASCO's many programs and activities, including cancer research, learning opportunities for oncology professionals, patient and caregiver education, and more. false false 7872001 6105844 PROFESSIONAL EDUCATION - CCF HELPS ONCOLOGISTS WORLDWIDE STAY UP TO DATE ON THE LATEST DEVELOPMENTS AND DISCOVERIES IN CANCER KNOWLEDGE. CCF SUPPORTS THE EFFORTS OF ASCO TO PROVIDE THE LATEST INFORMATION AND PROVIDE EDUCATION TO PHYSICIANS, RESEARCHERS AND CAREGIVERS. THIS WORK PROVIDES A DIRECT IMPACT AND BENEFIT TO EVERY CANCER PATIENT IN THE U.S. AND AROUND THE WORLD BY DEVELOPING AND COMMUNICATING THE MOST ADVANCED TREATMENT PROTOCOLS DEVELOPED BY ASCO PHYSICIANS. FUNDS FROM CCF ARE USED TO SUPPORT ASCO'S COMPREHENSIVE SCIENTIFIC AND EDUCATIONAL PROGRAMS THAT PROVIDE THE LATEST DATA TO CANCER DOCTORS AND OTHER HEALTHCARE PROFESSIONALS WORLDWIDE THROUGH BOTH LIVE MEETINGS AND PRINT AND ELECTRONIC EDUCATION OFFERINGS. HIGHLIGHTS OF THE PROFESSIONAL EDUCATIONAL AND SCIENTIFIC MEETINGS SUPPORTED BY CCF AND PRESENTED TO THE PUBLIC IN 2016 INCLUDE THE FOLLOWING: THE ASCO ANNUAL MEETING FEATURED MORE THAN 400 EDUCATIONAL AND SCIENTIFIC SESSIONS. OVER 5,400 ABSTRACTS WERE PRESENTED OR PUBLISHED. THE ASCO ANNUAL MEETING IS CONSIDERED THE PREMIER EDUCATIONAL AND SCIENTIFIC EVENT IN THE ONCOLOGY COMMUNITY AND ATTRACTS MORE THAN 38,000 ATTENDEES WORLDWIDE. THE MEETING IS DESIGNED TO ADVANCE THE EDUCATION OF PHYSICIANS AND OTHER PROFESSIONALS INVOLVED IN MULTIDISCIPLINARY CLINICAL CANCER CARE, TO SUPPORT THE DEVELOPMENT OF CLINICAL CANCER RESEARCHERS AND TO FACILITATE THE DELIVERY OF HIGH-QUALITY HEALTH CARE TO PATIENTS WITH CANCER. SESSIONS ARE DESIGNED TO PROVIDE MEETING ATTENDEES OPTIMUM LEARNING EXPERIENCES THROUGH DISEASE-SPECIFIC TOPICS AND ONCOLOGY-RELATED SUBJECTS. GASTROINTESTINAL CANCERS (GI) SYMPOSIUM - THE ANNUAL GI SYMPOSIUM IS THE PREMIERE MULTIDISCIPLINARY GI CANCER SCIENTIFIC AND EDUCATIONAL MEETING OFFERING THE MOST UP-TO-DATE STRATEGIES IN PREVENTION, SCREENING, AND TREATMENT OF GASTROINTESTINAL CANCERS. THE SYMPOSIUM IS JOINTLY DEVELOPED BY THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION INSTITUTE, ASCO, THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY, AND THE SOCIETY OF SURGICAL ONCOLOGY. GENITOURINARY CANCERS (GU) SYMPOSIUM - THE ANNUAL GU SYMPOSIUM IS THE PREEMINENT GENITOURINARY CANCER SCIENTIFIC AND EDUCATIONAL MEETING PROVIDING THE LATEST STRATEGIES IN SCREENING, DIAGNOSIS, TREATMENT, MANAGEMENT AND CONTROVERSIES IN THE FIELD OF GENITOURINARY CANCERS. THE SYMPOSIUM IS JOINTLY DEVELOPED BY ASCO, THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY, AND THE SOCIETY OF UROLOGIC ONCOLOGY. BEST OF ASCO - THE BEST OF ASCO MEETING PROGRAM CONDENSES HIGHLIGHTS FROM THE ASCO ANNUAL MEETING INTO A TWO DAY EDUCATIONAL MEETING, WHICH PROVIDES A UNIQUE, INTIMATE FORUM FOR THE PRESENTATION AND DISCUSSION OF THE PRACTICE-CHANGING SCIENCE AND EDUCATIONAL HIGHLIGHTS THAT WERE PRESENTED. A PANEL OF ASCO EXPERTS SELECTS ABSTRACTS THAT HIGHLIGHT THE IMPORTANT SCIENTIFIC INFORMATION TO CREATE THE BEST OF ASCO MEETING PROGRAM. THIS PROGRAM PROVIDES ACCESS TO THE MOST CUTTING-EDGE, PRACTICE-CHANGING RESEARCH PRESENTED AT THE MEETING IN A RESPONSIBLE, PEER-REVIEWED MANNER. PALLIATIVE CARE IN ONCOLOGY SYMPOSIUM - THE PALLIATIVE CARE IN ONCOLOGY SYMPOSIUM IS AN EDUCATIONAL OPPORTUNITY FOR ONCOLOGY PROFESSIONALS THAT PROVIDES OPPORTUNITIES FOR ATTENDEES TO LEARN HOW TO INTEGRATE PALLIATIVE CARE SKILLS INTO CANCER CARE ACROSS THE TRAJECTORY OF THE ILLNESS. THE SYMPOSIUM IS COSPONSORED BY FOUR LEADING MEDICAL SPECIALTY SOCIETIES: THE AMERICAN ACADEMY OF HOSPICE AND PALLIATIVE MEDICINE (AAHPM), ASCO, THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) AND THE MULTINATIONAL ASSOCIATION OF SUPPORTIVE CARE IN CANCER (MASCC). HIGHLIGHTS OF PRINT AND ELECTRONIC PROFESSIONAL EDUCATION MATERIALS SUPPORTED BY CCF AND AVAILABLE TO THE PUBLIC IN 2016 INCLUDE THE FOLLOWING: PROCEEDINGS - THE PROCEEDINGS PUBLICATIONS FOR THE ASCO ANNUAL MEETING AND SELECT COSPONSORED THEMATIC SYMPOSIA CONTAIN ALL THE ABSTRACTS SELECTED FOR PRESENTATION AT THE LIVE EDUCATIONAL MEETING AND ALLOWS THOSE NOT ABLE TO ATTEND ACCESS TO THE GROUND-BREAKING ABSTRACTS THAT WERE PRESENTED. EDUCATIONAL BOOKS -THE ASCO ANNUAL MEETING EDUCATIONAL BOOK IS THE COMPREHENSIVE RESOURCE FOR EDUCATION SESSION MATERIALS FROM THE ASCO ANNUAL MEETING, ALLOWING THE ENTIRE ONCOLOGY COMMUNITY TO BENEFIT FROM DISCUSSIONS OF CRITICAL RESEARCH UPDATES IN A POINT-OF-CARE CONTEXT. MANUSCRIPTS DISCUSS THE CURRENT STANDARDS OF CARE AND EXISTING TECHNOLOGIES BUT ALSO LOOK TOWARD THE FUTURE, DISCUSSING RESEARCH IMPROVEMENTS AND TRENDS AND TREATMENTS STILL ON THE HORIZON. ABSTRACTS ON ASCO.ORG - ABSTRACTS ON ASCO.ORG PROVIDE THE RESULTS OF THE LATEST CLINICAL CANCER RESEARCH TO HEALTHCARE PROFESSIONALS INVOLVED IN MULTIDISCIPLINARY CLINICAL CANCER CARE. THE ABSTRACTS ON ASCO.ORG COMPRISE ASCO'S COMPREHENSIVE ONLINE DATABASE OF ONCOLOGY-RELATED RESEARCH ABSTRACTS FROM ASCO SCIENTIFIC AND EDUCATIONAL MEETINGS DATING BACK TO 1995. VIRTUAL MEETINGS ON ASCO.ORG - THE ASCO VIRTUAL MEETING INTERFACE USES THE LATEST TECHNOLOGY TO ALLOW USERS TO VIEW AND REVIEW SESSIONS FROM THE ASCO ANNUAL MEETING AND CO-SPONSORED THEMATIC SYMPOSIA. VIEWERS CAN STAY ABREAST OF THE LATEST ONCOLOGY DEVELOPMENTS, VIEW MEETING SESSIONS THAT THEY WERE UNABLE TO ATTEND, OR REVIEW PRESENTATIONS AT THE TIME AND PLACE MOST CONVENIENT FOR THEM AT HOME, ON THE ROAD, OR IN THE OFFICE. VIRTUAL MEETING FEATURES MORE THAN 25,000 ORAL PRESENTATIONS, ABSTRACTS, AND POSTERS FROM MEETINGS DATING BACK TO 1999 THE MOST COMPREHENSIVE COLLECTION OF ONCOLOGY-RELATED MULTIMEDIA (SLIDES AND AUDIO) LECTURES AVAILABLE ON THE WEB. ASCO UNIVERSITY - ASCO UNIVERSITY IS AN ONLINE PLATFORM THAT PROVIDES EDUCATION FOR ONCOLOGY PROFESSIONALS. COURSE CONTENT IS DEVELOPED AND PRESENTED BY RECOGNIZED EXPERTS. ASCO UNIVERSITY SERVES AS THE EDUCATIONAL HOME AND SOURCE FOR SELF-DIRECTED LEARNING ACTIVITIES FOR PRACTICING ONCOLOGISTS AND THE NEXT GENERATION OF FELLOWS AND RESIDENTS. THE ACTIVITIES ON ASCO UNIVERSITY INCORPORATE FLEXIBLE, ROBUST CURRICULA WITH COLLATERAL PRODUCTS THAT TRANSLATE KEY ADULT LEARNING PRINCIPLES INTO INTERACTIVE EDUCATIONAL EXPERIENCES. 7222946 6669951 RESEARCH - IN THIS AGE OF SCIENTIFIC PROMISE, FEDERAL FUNDS FOR CANCER RESEARCH ARE DECLINING. FULFILLING THE PROMISE OF TODAY'S ADVANCES REQUIRES FUNDING FOR RESEARCH PROJECTS AND SUPPORT FOR INVESTIGATORS WHO WISH TO PURSUE A CAREER IN CLINICAL AND TRANSLATIONAL CANCER RESEARCH. WITHOUT CONTINUED, WELL-TARGETED RESEARCH, THERE WOULD BE NO MEANINGFUL PROGRESS. CCF PRIDES ITSELF ON ITS STANDARDS FOR SCIENTIFIC RIGOR, IMPLEMENTING A MULTISTAGE PEER REVIEW PROCESS WITH THE PARTICIPATION OF GLOBALLY RECOGNIZED SCIENTISTS, ONCOLOGISTS, AND BIOSTATISTICIANS IN THE SELECTION OF MERITORIOUS RESEARCH FOR FUNDING. SINCE 1984, CCF AND ASCO HAVE FUNDED MORE THAN $100 MILLION IN CANCER RESEARCH GRANTS TO OVER A THOUSAND RECIPIENTS. CCF FUNDS THE ENTIRE SPECTRUM OF RESEARCH ACTIVITIES RELATED TO CANCER PREVENTION, SCREENING, TREATMENT, AND OUTCOMES RESEARCH IN ALL CANCER TYPES, AND SUPPORTS PROGRESS BY FUNDING CANCER RESEARCHERS AT ALL STAGES OF THEIR CAREERS, ENABLING ONCOLOGY'S BEST AND BRIGHTEST TO PURSUE PROMISING RESEARCH. EACH YEAR, CCF FUNDS AND AWARDS MULTIPLE RESEARCH GRANTS DESIGNED TO HELP ATTRACT AND RETAIN THE BEST SCIENTIFIC MINDS IN CANCER RESEARCH AND TO SUPPORT THEIR EFFORTS. HIGHLIGHTS OF 2016 RESEARCH ACTIVITIES AND ACCOMPLISHMENTS INCLUDE: ADVANCED CLINICAL RESEARCH AWARD (ACRA) - $450,000 PROVIDED ONE (1) THREE-YEAR AWARD INTENDED TO FUND AN INVESTIGATOR COMMITTED TO CLINICAL CANCER RESEARCH AND WHO IS CONDUCTING ORIGINAL RESEARCH IN BREAST CANCER. CAREER DEVELOPMENT AWARD (CDA) - $2,000,000 PROVIDED ELEVEN (11) THREE-YEAR AWARDS INTENDED TO SUPPORT CLINICAL RESEARCH OF CLINICAL INVESTIGATORS WHO HAVE RECEIVED THEIR INITIAL FACULTY APPOINTMENTS AND ARE ESTABLISHING INDEPENDENT CLINICAL CANCER RESEARCH PROGRAMS. YOUNG INVESTIGATOR AWARD (YIA) - $2,825,000 PROVIDED FIFTY-SEVEN (57) ONE-YEAR AWARDS DESIGNED TO ENCOURAGE AND PROMOTE HIGH-QUALITY RESEARCH IN CLINICAL ONCOLOGY BY PROVIDING FUNDS TO PROMISING INVESTIGATORS DURING THE TRANSITION FROM A FELLOWSHIP PROGRAM TO A FACULTY APPOINTMENT. LONG-TERM INTERNATIONAL FELLOWSHIP (LIFE) - $460,000 PROVIDED FOUR (4) ONE-YEAR FELLOWSHIPS TO EARLY-CAREER ONCOLOGISTS FROM LOW TO MIDDLE INCOME COUNTRIES FOR THE SUPPORT AND RESOURCES NEEDED TO ADVANCE THEIR TRAINING BY DEEPENING THEIR RELATIONSHIPS WITH AMERICAN, CANADIAN, OR EUROPEAN COLLEAGUES AND THEIR U.S. ,CANADIAN, OR EU INSTITUTIONS. INTERNATIONAL INNOVATION GRANT - $80,000 PROVIDED FOUR (4) ONE-YEAR AWARDS IN SUPPORT OF NOVEL AND INNOVATIVE PROJECTS THAT CAN HAVE A SIGNIFICANT IMPACT ON CANCER CONTROL IN LOW- AND MIDDLE-INCOME COUNTRIES (LMCS). GIANNI BONADONNA BREAST CANCER RESEARCH FELLOWSHIP - $75,000 PROVIDED ONE (1) ONE-YEAR FELLOWSHIP THAT ENABLES AN EARLY-CAREER INVESTIGATOR TO UNDERTAKE A BREAST CANCER PROJECT UNDER THE MENTORSHIP OF THE GIANNI BONADONNA BREAST AWARD RECIPIENT. THE JAMES B. NACHMAN JUNIOR FACULTY AWARD IN PEDIATRIC ONCOLOGY WAS ESTABLISHED IN MEMORY OF JAMES B. NACHMAN, MD, AN INTERNATIONALLY RENOWNED PEDIATRIC CANCER EXPERT AND PEDIATRICS PROFESSOR. HE CHAIRED SEVERAL CHILDREN'S ONCOLOGY GROUP NATIONAL STUDY COMMITTEES AND WAS AN AUTHORITY IN THE MEDICAL MANAGEMENT OF CHILDHOOD CANCERS, ESPECIALLY LEUKEMIA AND LYMPHOMA. $3,000 PROVIDED FOR ONE JUNIOR FACULTY MEMBER WITH THE HIGHEST-SCORING ABSTRACT IN PEDIATRIC ONCOLOGY TO PRESENT THE ABSTRACT AT THE ASCO ANNUAL MEETING. MERIT AWARDS- $136,000 PROVIDED FOR 133 MERIT AWARDS WHICH PROMOTE CLINICAL RESEARCH BY AWARDING YOUNG SCIENTISTS WHOSE RESEARCH IS ADDRESSED IN HIGH QUALITY ABSTRACTS SUBMITTED TO ASCO MEETINGS WITH AN OPPORTUNITY TO PRESENT THEIR RESEARCH AND INTERACT WITH OTHER CLINICAL CANCER INVESTIGATORS AT ASCO SCIENTIFIC MEETINGS AND DISEASE-SPECIFIC SYMPOSIA. ONCOLOGY TRAINEE TRAVEL AWARDS- $17,360 PROVIDED FOR 28 TRAVEL AWARDS TO ALLOW FOR THE SUPPORT OF CONTINUING EDUCATION AND PROFESSIONAL DEVELOPMENT OF TRAINEE ONCOLOGISTS BY PROVIDING THEM INDIVIDUAL TRAVEL GRANTS TO DEFRAY TRAVEL EXPENSES FOR ATTENDING THE ASCO ANNUAL MEETING. 6545711 5224150 QUALITY AND ACCESS TO CARE - REMARKABLE ADVANCES IN CANCER MEDICINE ARE OCCURRING MORE AND MORE FREQUENTLY, YET THE FULL PROMISE OF SUCH PROGRESS CANNOT BE REALIZED UNTIL HIGH-QUALITY CANCER CARE IS AVAILABLE TO EVERYONE. CCF IS KEENLY AWARE OF THE POTENTIALLY FATAL DIVIDE BETWEEN THOSE WITH ACCESS TO THE FRUITS OF RESEARCH AND TIMELY CARE AND THOSE WITHOUT. WE SEEK TO CONFRONT THESE DISPARITIES AND IMPROVE THE OUTLOOK FOR EVERY PERSON TOUCHED BY CANCER BY SUPPORTING PROGRAMS THAT INCREASE ACCESS TO CARE IN ALL COMMUNITIES, INCLUDING THOSE UNDERSERVED. THE QUALITY AND ACCESS TO CARE PROGRAMS AND INITIATIVES SUPPORTED BY CCF IN 2016 INCLUDE THE FOLLOWING: CANCERLINQ - CANCERLINQ IS A BIG DATA PROJECT THAT AIMS TO RAPIDLY IMPROVE THE OVERALL QUALITY OF CANCER CARE. CANCERLINQ IS BASED ON A CUTTING-EDGE HEALTH IT PLATFORM THAT WILL POWERFULLY CONNECT AND ANALYZE REAL-WORLD CANCER CARE DATA FROM ALMOST ANY ELECTRONIC RECORD SOURCE. CANCERLINQ WILL BE ABLE TO: PROVIDE REAL-TIME QUALITY FEEDBACK TO PROVIDERS; UNCOVER PATTERNS THAT CAN IMPROVE CARE; FEED PERSONALIZED INSIGHTS TO DOCTORS. STATE/REGIONAL AFFILIATE PROGRAM - THE ASCO STATE/REGIONAL AFFILIATE PROGRAM IS DESIGNED TO ADDRESS ISSUES IN THE PRACTICE OF ONCOLOGY ON THE LOCAL LEVEL. THE PROGRAM INCLUDES FACILITATION OF INTERACTION AMONG ASCO AND 49 STATE OR REGIONAL ONCOLOGY SOCIETIES THAT HAVE ACCESS TO THE SOCIETY'S EXPERTISE AND GUIDANCE ON WAYS TO STRENGTHEN THEIR ORGANIZATIONS, ENHANCE THEIR EDUCATIONAL ACTIVITIES, AND PROVIDE ADVOCACY SUPPORT, EDUCATION AND RESOURCES ON PRACTICE-RELATED ISSUES, AND A WEBSITE DEVELOPMENT TOOL. DIVERSITY IN ONCOLOGY INITIATIVE - THE CCF GRANTS AND AWARDS PROGRAM PROVIDES FUNDING FOR DIFFERENT TYPES OF AWARD OPPORTUNITIES FOR ONCOLOGY FELLOWS, CLINICAL PRACTICES, AND INTERNATIONAL RESEARCHERS. ONE OF THE PROGRAMS OFFERED THROUGH CCF IS THE DIVERSITY IN ONCOLOGY INITIATIVE. THE DIVERSITY IN ONCOLOGY INITIATIVE WAS STRUCTURED TO FACILITATE THE RECRUITMENT AND RETENTION OF INDIVIDUALS FROM POPULATIONS UNDERREPRESENTED IN MEDICINE TO CANCER CAREERS, WITH PARTICULAR ATTENTION TO THE DEVELOPMENT OF CLINICAL PRACTITIONERS AND INVESTIGATORS. 844477 319518 22485135 true true false false false false false false false true false false false false false true true true false false true true true false false false false true true true false false false false false false false false false false false false false true false false false true 135 0 true 0 false false false false false true true false false false false X 15 14 true false true false false true true true true false false true true true true true true false false false AL AK AZ AR CA CO CT FL GA HI IL KS KY ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X ERIN HULTMAN 5714831300 2318 MILL ROAD STE 800 ALEXANDRIA VA 22314 Thomas Roberts Jr MD Chair 1.0 1.0 X X 0 0 0 Sandra Swain MD FACP Treasurer 1.0 0.0 X X 0 0 0 Claire Huang Secretary 1.0 0.0 X X 0 0 0 Clifford Hudis MD FASCO CEO AS OF 6/27/2016 7.5 30.0 X X 0 370577 764 Allen S Lichter MD FASCO CEO TO 6/27/2016 7.5 30.0 X X 0 579036 21869 Nancy Daly MS MPH EXECUTIVE VP & CHIEF PHLTP OFC 36.5 1.0 X X 0 316634 33445 Daniel Hayes MD FACP FASCO ASCO President 1.0 1.0 X 0 0 0 Alexander W Casdin Board Member 1.0 0.0 X 0 0 0 John H Glick MD FASCO Board Member 1.0 0.0 X 0 0 0 Thomas Marsland MD FASCO Board Member 1.0 0.0 X 0 0 0 Lawrence H Einhorn MD FASCO Board Member 1.0 0.0 X 0 0 0 Gabriel HortobagyiMDFACPFASCO Board Member 1.0 0.0 X 0 0 0 W Charles Penley MD FASCO Board Member 1.0 0.0 X 0 0 0 Raj Mantena RPh Board Member 1.0 0.0 X 0 0 0 Robert Mayer MD FASCO Board Member 1.0 0.0 X 0 0 0 Margaret Tempero MD FASCO Board Member 1.0 0.0 X 0 0 0 Steven Rosen MD FACP Board Member 1.0 0.0 X 0 0 0 Aaron Sasson Board Member 1.0 0.0 X 0 0 0 Erin Hultman CPA MST CFO 7.5 30.0 X 0 207861 30555 0 1474108 86633 0 false true false GSW WORLDWIDE PO BOX 505214 ST LOUIS MO 63150 CAMPAIGN CONSULTING 134705 1 16740 5978000 17164102 22601 23158842 0 877067 877067 0 0 0 0 0 13732389 13193342 539047 539047 539047 0 0 0 0 0 0 0 0 0 0 24574956 1416114 17270675 17270675 732700 732700 316088 316088 0 0 0 0 0 0 0 4463451 3175827 249218 1038406 0 23973 23973 0 0 130826 130826 1185095 294885 40275 849935 1086929 87866 5000 994063 58529 8633 10541 39355 490553 134201 356352 0 240240 240240 369272 89050 117142 163080 0 158212 6183 50856 101173 0 0 0 0 POSTAGE 542042 9446 12030 520566 DUES & SUBSCRIPTIONS 150814 3465 73813 73536 BANK & CREDIT CARD FEES 26475 126 26324 25 ALLOCATION OF ADMIN OVERHEAD 490191 -667797 177606 27245874 22485135 446642 4314097 5830823 8326628 0 0 17921408 10381142 0 0 0 0 0 0 0 0 0 0 26416 80744 0 0 38490854 40067933 0 0 0 0 0 0 899544 1341448 63169045 60197895 885130 578082 3141677 3156677 1250413 943675 0 0 0 0 0 0 0 0 0 0 0 0 5277220 4678434 X 28196097 30337459 20344037 14466311 9351691 10715691 57891825 55519461 63169045 60197895 -2670918 298554 X false true X true false X 25403476 24662684 36399446 29974390 23158842 139598838 0 0 25403476 24662684 36399446 29974390 23158842 139598838 47588774 92010064 925185 927924 929857 833497 877067 4493530 0 0 144092368 0.63855 0.69527 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 9169527 1364000 280187 450500 10363214 3968976 5417500 -94449 122500 9169527 4031095 9750 110331 182200 3968976 2605326 1320000 107969 2200 4031095 82699 2517200 7627 2200 2605326 1.00000 false false 0 0 X 24742685 298554 298554 24444131 130825 130825 24574956 27376699 27376699 -130825 -130825 27245874 PART V, LINE 4 Permanently restricted net assets of donor-restricted endowment funds are preserved, absent explicit direction from the donor. Interest from the permanently restricted funds is intended to fund future research and/or educational awards. PART V, LINE 1A-1G ENDOWMENT FUNDS ARE BASED ON GAAP AND AGREE TO THE RESTRICTED FUNDS ON THE AUDITED FINANCIAL STATEMENTS. PART X, LINE 2 IN ACCORDANCE WITH GAAP, THE FOUNDATION MAY RECOGNIZE THE TAX BENEFIT FROM AN UNCERTAIN TAX POSITION ONLY IF IT IS MORE LIKELY THAN NOT THAT THE TAX POSITION WILL BE SUSTAINED AN EXAMINATION BY TAXING AUTHORITIES, BASED ON THE TECHNICAL MERITS OF THE POSITION. THE TAX BENEFITS RECOGNIZED IN THE FINANCIAL STATEMENTS FROM SUCH A POSITION ARE MEASURED BASED ON THE LARGEST BENEFIT THAT HAS A GREATER THAN 50% LIKELIHOOD OF BEING REALIZED UPON ULTIMATE SETTLEMENT. THE FOUNDATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR TAX POSITIONS TAKEN, AND THEREFORE, DOES NOT HAVE UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS. GENERALLY, THE FOUNDATION IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS BEFORE DECEMBER 31, 2013. true East Asia and the Pacific Program Services AWARD & GRANTS 34360 Europe (Including Iceland and Greenland) Program Services AWARD & GRANTS 28140 North America Program Services AWARD & GRANTS 181500 South America Program Services AWARD & GRANTS 7660 South Asia Program Services AWARD & GRANTS 47240 Sub-Saharan Africa Program Services AWARD & GRANTS 5384 Central America and the Caribbean Program Services AWARD & GRANTS 8500 Middle East and North Africa Program Services AWARD & GRANTS 3304 Central America and the Caribbean Investments 2914437 3230525 3230525 East Asia and the Pacific INT'L INNOVATION GRANT 20000 CASH/CHECK North America YOUNG INVESTIGATOR AWARD 100000 CASH/CHECK South Asia INT'L INNOVATION GRANT 40000 CASH/CHECK 3 AWARDS East Asia and the Pacific 15 15620 cash/check AWARDS Europe (Including Iceland and Greenland) 26 26880 cash/check AWARDS North America 23 81500 cash/check AWARDS South America 7 7660 cash/check AWARDS Central America and the Caribbean 2 8500 cash/check AWARDS Middle East and North Africa 3 3304 cash/check AWARDS Sub-Saharan Africa 4 5200 cash/check AWARDS South Asia 6 7240 CASH/CHECK false false false false false false PART I, LINE 2: EXPLANATION: CCF GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CCF'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES ARE REQUIRED TO SIGN A GRANT AGREEMENT WITH CCF THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST CCF'S APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE TO CCF AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CCF'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CCF AND REQUEST A NO-COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT OR TO MEET THE PROPOSED TIME SCHEDULES. GRANTEES ARE REQUIRED TO NOTIFY CCF IF THEY PLAN TO LEAVE AN ORGANIZATION DURING THE COURSE OF A GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL YEARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO THE REVIEW AND APPROVAL OF CCF. CCF REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (FINANCIAL REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND A BUDGET SUMMARY ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF THE GRANT BUDGET PERIOD. CCF REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. CCF REQUIRES A FINAL PROJECT REPORT AND BUDGET SUMMARY WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CCF REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED TO CCF. GRANTS ARE ADMINISTRATIVELY CLOSED BY CCF AFTER RECEIPT OF THE FINAL PROJECT REPORT AND FINAL BUDGET SUMMARY AND AFTER CCF'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS IN THE GRANT HAVE BEEN MET. CCF RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENTLY WITH THE APPROVED BUDGET. true Baylor College of Medicine One Baylor Plaza Houston TX 77030 741613878 501(C)(3) 100000 GBBCRF, YIA Beth Israel Deaconess Medical Center 330 Brookline Ave E Boston MA 02215 422103881 501(C)(3) 50000 YIA Brigham and Women's Hospital 75 Francis Street Boston MA 02115 422312909 501(C)(3) 200000 CDA Cedars-Sinai Medical Center 8700 Beverly Blvd Los Angeles CA 90048 951644600 501(C)(3) 50000 YIA City of Hope 1500 East Duarte Road Duarte CA 91010 951683875 501(C)(3) 115000 LTIF Columbia University Medical Center 630 West 168th Street New York NY 10032 135598093 501(c)(3) 50000 YIA Dana-Farber Cancer Institute 44 Binney Street Boston MA 02115 422263040 501(C)(3) 350000 YIA Dartmouth-Hitchcock Medical Center One Medical Center Dr Lebanon NH 03756 222715483 501(C)(3) 200000 CDA David Geffen School of Medicine at UCLA 10833 Le Conte Ave Los Angeles CA 90095 954373071 501(C)(3) 50000 YIA Fred Hutchinson Cancer Research Center 1100 Fairview Ave N Seattle WA 98109 237156071 501(C)(3) 50000 YIA George Washington University George Washington Uni Washington DC 20037 530196584 501(C)(3) 50000 YIA H Lee Moffitt Cancer CTR & Research Inst 12902 Magnolia Drive Tampa FL 33612 592451713 501(C)(3) 200000 CDA Harvard Medical School 25 Shattuck Street Boston MA 02115 042103580 501(C)(3) 8500 MSRA Icahn School of Medicine at Mount Sinai 5 E 98th St New York NY 10029 136171197 501(C)(3) 50000 YIA Georgetown University 3800 Reservoir Road Washington DC 20057 530196603 501(C)(3) 50000 YIA Massachusetts General Hospital 55 Fruit Street Boston MA 02114 426979834 501(C)(3) 100000 YIA Mayo Clinic Minnesota 200 First St SW Rochester MN 55905 416011702 501(C)(3) 115000 LTIF Memorial Sloan Kettering Cancer Ctr (MSKCC) 1275 York Avenue New York NY 10065 131624182 501(C)(3) 1308500 CDA, YIA, MSRA Montefiore Medical Center 111 East 210th Street Bronx NY 10467 131740114 501(C)(3) 50000 YIA New York University (NYU) School of Med 550 First Avenue New York NY 10016 135562309 501(C)(3) 50000 YIA Oregon Health & Science University (OHSU) 3181 SW Sam JKSN Park Rd PortlD OR 97239 131176109 501(C)(3) 100000 YIA Seattle Children's Hospital 1100 Olive Way Seattle WA 98101 910564748 501(C)(3) 50000 YIA Stanford University 800 Welch Road Stanford CA 94305 941156365 501(C)(3) 300000 CDA, YIA The Ohio State University 300 W 10th Ave Columbus OH 43210 316025986 501(C)(3) 50000 YIA The University of Chicago 5841 South Maryland Ave Chicago IL 60637 362177139 501(C)(3) 150000 YIA The University of North Carolina at Chapel Hill 102 Mason Farm Rd Chapel Hill NC 27599 566001393 501(C)(3) 500000 ACRABC, YIA The University of Texas MD Anderson Cancer Ctr 1515 Holcombe Blvd Houston TX 77030 746001118 501(c)(3) 615000 CDA, YIA, LTIF University of California San Diego 3855 Health Sciences Dr La Jolla CA 92093 426979830 501(C)(3) 50000 YIA University of California San Francisco 2340 Sutter Street San Francisco CA 94115 946036493 501(C)(3) 50000 YIA University of Colorado Denver 13001 E 17th Place Aurora CO 80045 846000555 501(C)(3) 50000 YIA University of Illinois at Chicago 1737 West Polk Street Chicago IL 60612 376000511 501(C)(3) 8500 MSRA University of Illinois College of Medicine 1901 S1ST STA Urbana IL 61820 376000511 501(C)(3) 8500 MSRA University of Michigan 1500 EMeD CTR Dr Ann Arbor MI 48109 386006309 501(C)(3) 250000 CDA, YIA University of Pennsylvania 16th Fl Penn Tower Philadelphia PA 19104 231352685 501(C)(3) 50000 YIA University of Pittsburgh UPMC Cancer Pavilion Pittsburgh PA 15232 250965591 501(C)(3) 50000 YIA Vanderbilt University Medical Center 691 Preston RSRCH Bldg Nashville TN 38105 620476822 501(C)(3) 50000 YIA Yale University 333 Cedar Street New Haven CT 06520 060646973 501(C)(3) 100000 YIA American Society of Clinical Oncology 2318 Mill Rd800 Alexandria VA 22314 136180380 501(C)(3) 11641675 CONTRIBUTION 38 Merit Awards 133 136000 Patient Advocate Scholarships 41 103430 Oncology Trainee Travel Awards 28 17360 PART I, LINE 2 CCF GRANTS ARE AWARDED BASED ON MERIT THROUGH A PEER-REVIEW PROCESS CONDUCTED BY MEMBERS OF CCF'S GRANT SELECTION COMMITTEE USING ELIGIBILITY CRITERIA ESTABLISHED FOR EACH SPECIFIC GRANT. GRANTEES ARE REQUIRED TO SIGN A GRANT AGREEMENT WITH CCF THAT ESTABLISHES CERTAIN REQUIREMENTS FOR THE GRANT. GRANTEES MUST REQUEST CCF'S APPROVAL FOR ANY CHANGES IN THE GRANT PROJECT AND THE GRANTEE'S STATUS. GRANTEES MUST SUBMIT A FORMAL REQUEST FOR A CHANGE IN OBJECTIVES OR SCOPE TO CCF AND INCLUDE JUSTIFICATION FOR THE CHANGES, WHICH IS SUBJECT TO CCF'S REVIEW AND APPROVAL. GRANTEES ARE REQUIRED TO NOTIFY CCF AND REQUEST A NO-COST EXTENSION IF THERE ARE SIGNIFICANT DELAYS THAT WILL MATERIALLY AFFECT THE ABILITY TO ATTAIN THE OBJECTIVES OF THE GRANT PROJECT OR TO MEET THE PROPOSED TIME SCHEDULES. GRANTEES ARE REQUIRED TO NOTIFY CCF IF THEY PLAN TO LEAVE AN ORGANIZATION DURING THE COURSE OF A GRANT AND MUST SUBMIT A REQUEST FOR APPROVAL OF INSTITUTION TRANSFER OF THE GRANT BEFORE ANY TRANSFER TAKES PLACE. CHANGES OF GREATER THAN 5% OF THE TOTAL YEARLY GRANT BUDGET BETWEEN OR INTO NEW BUDGET CATEGORIES ARE SUBJECT TO THE REVIEW AND APPROVAL OF CCF. CCF REQUIRES TECHNICAL PROJECT REPORTS (PROGRESS REPORTS) AND BUDGET SUMMARIES (FINANCIAL REPORTS) FOR ALL GRANTS. UNLESS OTHERWISE SPECIFIED IN THE GRANT TERMS AND CONDITIONS, AN ANNUAL PROGRESS REPORT AND A BUDGET SUMMARY ARE REQUIRED TO BE SUBMITTED WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING THE END OF THE GRANT BUDGET PERIOD. CCF REVIEWS THE REPORTS AND PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. CCF REQUIRES A FINAL PROJECT REPORT AND BUDGET SUMMARY WITHIN 30 DAYS AND 60 DAYS, RESPECTIVELY, FOLLOWING EXPIRATION OF THE GRANT. CCF REVIEWS THE REPORTS AND IF APPROVED, PROVIDES THE GRANTEE AN APPROVAL NOTIFICATION. ALL UNUSED FUNDS AT THE END OF THE AWARD TERM MUST BE RETURNED TO CCF. GRANTS ARE ADMINISTRATIVELY CLOSED BY CCF AFTER RECEIPT OF THE FINAL PROJECT REPORT AND FINAL BUDGET SUMMARY AND AFTER CCF'S DETERMINATION THAT ANY OTHER ADMINISTRATIVE REQUIREMENTS IN THE GRANT HAVE BEEN MET. CCF RESERVES THE RIGHT TO ASK THE GRANTEE TO RETURN FUNDS THAT WERE SPENT INCONSISTENTLY WITH THE APPROVED BUDGET. part II, award abbreviations: GBBCRF: Gianni Bonadonna Breast Cancer Research Fellowship YIA: Young investigator award CDA: Career Development award LTIF: long-term international fellowship MSRA: Medical Student Rotation Award ACRABC: advanced Clinical REsearch award in breast cancer false false false false false false false false false Clifford Hudis MD FASCO CEO AS OF 6/27/2016 0 360577 0 0 0 10000 0 0 0 764 0 371341 0 0 Allen S Lichter MD FASCO CEO TO 6/27/2016 0 360976 0 144106 0 73954 0 19875 0 1994 0 600905 0 0 Nancy Daly MS MPH EXECUTIVE VP & CHIEF PHLTP OFC 0 294615 0 5000 0 17019 0 19875 0 13570 0 350079 0 0 Erin Hultman CPA MST CFO 0 201861 0 6000 0 0 0 15140 0 15415 0 238416 0 0 PART I, LINE 3: EXPLANATION: COMPENSATION IS ESTABLISHED BY A RELATED ORGANIZATION, THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, INC. THE METHODS USED BY ASCO TO DETERMINE COMPENSATION ARE: COMPENSATION COMMITTEE; INDEPENDENT COMPENSATION CONSULTANT; FORMS 990 OF OTHER ORGANIZATIONS, WRITTEN EMPLOYMENT CONTRACT; COMPENSATION STUDY OR SURVEY; AND APPROVAL BY BOARD OR COMPENSATION COMMITTEE. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES PATIENT EDUCATION AND INFORMATION - WELL-INFORMED, EDUCATED PATIENTS ARE THEIR OWN BEST ADVOCATES, AS WELL AS INVALUABLE PARTNERS FOR DOCTORS. CCF SUPPORTS PROGRAMS AND ACCURATE, DOCTOR-APPROVED CANCER INFORMATION AND RESOURCES BOTH IN PRINT AND ONLINE, THAT EDUCATE PATIENTS AND THE PUBLIC ABOUT CANCER CARE, TREATMENT, RESEARCH, PREVENTION, AND OTHER ISSUES IMPORTANT TO THE CANCER COMMUNITY. FUNDING IN THIS AREA ALLOWS CCF TO CONTINUE AND EXPAND OUR WORK TO INFORM PATIENTS. HIGHLIGHTS OF PATIENT EDUCATION AND INFORMATION PROGRAMS AND ACTIVITIES SUPPORTED BY CCF IN 2016 INCLUDE THE FOLLOWING: PATIENT ADVOCATE SCHOLARSHIP PROGRAM- THE PATIENT ADVOCATE SCHOLARSHIP PROGRAM PROVIDES TRAVEL GRANTS TO A SELECT NUMBER OF PATIENT ADVOCATES TO ATTEND THE ASCO ANNUAL MEETING AND COSPONSORED THEMATIC MEETINGS. IN 2016, $103,430 IN FUNDING ALLOWED 41 PATIENT ADVOCATES TO ATTEND THE ASCO ANNUAL MEETING AND COSPONSORED THEMATIC MEETINGS. CANCER.NET- CANCER.NET BRINGS THE EXPERTISE AND RESOURCES OF ASCO TO PEOPLE LIVING WITH CANCER AND THOSE WHO CARE FOR AND CARE ABOUT THEM. THE WEBSITE PROVIDES TIMELY, COMPREHENSIVE INFORMATION TO HELP PATIENTS AND FAMILIES MAKE INFORMED HEALTH CARE DECISIONS ALL CONTENT IS SUBJECT TO A FORMAL PEER-REVIEW PROCESS BY THE CANCER.NET EDITORIAL BOARD, COMPOSED OF MORE THAN 150 MEDICAL, SURGICAL, RADIATION, AND PEDIATRIC ONCOLOGISTS, PHYSICIAN ASSISTANTS, ONCOLOGY NURSES, SOCIAL WORKERS, AND PATIENT ADVOCATES AND INCLUDES PEER-REVIEWED INFORMATION ON MORE THAN 124 TYPES OF CANCER AND SYNDROMES, INCLUDING RISK FACTORS, DIAGNOSIS, FINDING AN ONCOLOGIST, TREATMENT, MANAGING SIDE EFFECTS, CLINICAL TRIALS, AND AFTER TREATMENT, CAREGIVING, COPING STRATEGIES, AND SURVIVORSHIP. INFORMATION IS DELIVERED IN WRITTEN ARTICLES, VIDEOS, AND AUDIO PODCASTS. THIS INFORMATION IS MADE AVAILABLE FREE TO THE PUBLIC. EXPENSES $363,200. INCLUDING GRANTS OF $103,430. REVENUE $0. INTERNATIONAL PROGRAMS - ASCO AND THE CONQUER CANCER FOUNDATION SHARE AN INTERNATIONAL MISSION TO ENGAGE THE PHYSICIAN AND THE HEALTHCARE PROFESSIONAL COMMUNITY ON A GLOBAL SCALE TO IMPROVE CARE TO CANCER PATIENTS AND ENHANCE THE EXCHANGE OF KNOWLEDGE TO FACILITATE ADVANCES IN THE CARE OF PEOPLE WITH CANCER EVERYWHERE. CCF FUNDS SUPPORT INTERNATIONAL PROGRAMS INCLUDING EDUCATION, FELLOWSHIP AND GRANT OPPORTUNITIES TO ENABLE ONCOLOGISTS FROM OPPOSITE ENDS OF THE WORLD TO SHARE IDEAS AND BUILD LASTING COLLABORATIONS THAT CAN ENHANCE PATIENT CARE LOCALLY AND GLOBALLY. CCF FUNDS SPECIFICALLY SUPPORTING INTERNATIONAL ACTIVITIES INCLUDE THE FOLLOWING: LONG-TERM INTERNATIONAL FELLOWSHIP (LIFE) PROVIDES EARLY-CAREER ONCOLOGISTS IN DEVELOPING NATIONS THE SUPPORT AND RESOURCES NEEDED TO ADVANCE THEIR TRAINING BY DEEPENING THEIR RELATIONSHIP WITH A UNITED STATES OR CANADIAN COLLEAGUE AND HIS OR HER INSTITUTION. THROUGH A ONE YEAR FELLOWSHIP THE RECIPIENT WILL EARN VALUABLE TRAINING AND EXPERIENCE WITH WHICH THEY CAN AFFECT CHANGE IN CANCER CARE IN THEIR HOME COUNTRY. RECIPIENTS MUST RETURN TO THEIR HOME INSTITUTIONS AFTER COMPLETING THEIR FELLOWSHIP AND ARE EXPECTED TO DISSEMINATE THE KNOWLEDGE THEY HAVE GAINED. INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD (IDEA)-THE INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD PROVIDES SUPPORT FOR ONCOLOGISTS IN DEVELOPING COUNTRIES TO PARTICIPATE IN THE ASCO ANNUAL MEETING AND VISIT A CANCER CENTER IN THE UNITED STATES OR CANADA. THIS AWARD WAS DESIGNED TO PROVIDE CONTINUING MEDICAL EDUCATION, ASSIST IN CAREER DEVELOPMENT AND HELP TO ESTABLISH STRONG RELATIONSHIPS WITH LEADING ASCO MEMBERS WHO SERVE AS SCIENTIFIC MENTORS TO EACH RECIPIENT. INTERNATIONAL INNOVATION GRANT (IIG) PROVIDES RESEARCH FUNDING IN SUPPORT OF NOVEL AND INNOVATIVE PROJECTS THAT CAN HAVE A SIGNIFICANT IMPACT ON CANCER CONTROL IN LOW- AND MIDDLE-INCOME COUNTRIES (LMCS). THE INTERNATIONAL INNOVATION GRANT PROGRAM IS INTENDED TO SUPPORT PROPOSALS OF UP TO $20,000 EACH THAT HAVE THE POTENTIAL TO REDUCE THE CANCER BURDEN IN LOCAL COMMUNITIES, WHILE ALSO BEING POTENTIALLY TRANSFERRABLE TO OTHER LOW- OR MIDDLE- INCOME SETTINGS. EXPENSES $481,277. INCLUDING GRANTS OF $216,088. REVENUE $0. FORM 990, PART VI, SECTION A, LINE 1 AS OF DECEMBER 31, 2016, THE BOARD OF DIRECTORS OF CCF INCLUDED FIFTEEN (15) DIRECTORS WITH VOTING RIGHTS AND TWO (2) DIRECTORS WITHOUT VOTING RIGHTS. FOURTEEN (14) DIRECTORS WITH VOTING RIGHTS WERE APPOINTED BY THE BOARD OF DIRECTORS OF ASCO, A NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION. THERE WERE THREE EX-OFFICIO DIRECTORS: THE CHIEF EXECUTIVE OFFICER (CEO) (WITH VOTING RIGHTS), THE ASCO PRESIDENT (WITHOUT VOTING RIGHTS) AND THE EXECUTIVE VICE PRESIDENT AND CHIEF PHILANTHROPIC OFFICER (WITHOUT VOTING RIGHTS). ALL VOTING MEMBERS OF THE BOARD OF DIRECTORS HAVE THE SAME VOTING RIGHTS. DURING THE REPORTED TAX YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS CONSISTENT WITH CCFS BYLAWS. THE EXECUTIVE COMMITTEE IS COMPOSED OF THE CHAIR, CEO, SECRETARY, TREASURER, EXECUTIVE VICE PRESIDENT AND CHIEF PHILANTHROPIC OFFICER, AND A SIXTH EXECUTIVE COMMITTEE MEMBER ELECTED BY THE DIRECTORS. ALL MEMBERS OF THE EXECUTIVE COMMITTEE EXCEPT THE EXECUTIVE VICE PRESIDENT AND CHIEF PHILANTHROPIC OFFICER ARE ENTITLED TO VOTE. ALL EXECUTIVE COMMITTEE MEMBERS ARE MEMBERS OF CCF'S BOARD OF DIRECTORS. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY CCF'S BYLAWS, WHICH PROVIDE THAT EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW AND EXCEPT AS SPECIFIED IN THE BYLAWS, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT DECISIONS BETWEEN BOARD MEETINGS AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED BOARD MEETING. ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH CCF'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 2 DR. CLIFFORD HUDIS, DR. ALLEN S. LICHTER, NANCY DALY, AND ERIN HULTMAN WERE ALL EMPLOYED BY ASCO. DR. CLIFFORD HUDIS, DR. ALLEN S. LICHTER, AND DR. THOMAS ROBERTS, JR. ALL SERVED ON THE ASCO BOARD OF DIRECTORS DURING 2016. DR. ALLEN S. LICHTER BECAME A CONSULTANT OF A COMPANY OWNED BY RAJ MANTENA AFTER HE RETIRED FROM HIS POSITION AS CEO AND AS A MEMBER OF THE CCF BOARD OF DIRECTORS DURING 2016. FORM 990, PART VI, SECTION A, LINE 4 IN 2016, THE BYLAWS WERE AMENDED TO REMOVE THE LIMIT ON THE NUMBER OF CONSECUTIVE TERMS THAT INDIVIDUALS COULD SERVE AS MEMBERS OF THE BOARD OF DIRECTOR, THE EXECUTIVE VICE PRESIDENT AND CHIEF PHILANTHROPIC OFFICER WAS ADDED AS AN EX OFFICIO MEMBER OF THE EXECUTIVE COMMITTEE, WITHOUT A VOTE, AND A REQUIREMENT THAT EACH MEMBER OF THE CCF BOARD OF DIRECTORS RECEIVE NOTICE OF A PROPOSED AMENDMENT OR REPEAL OF ANY OF THE BYLAWS WAS REMOVED, ALTHOUGH ANY AMENDMENT OR REPEAL OF THE BYLAWS MUST STILL BE APPROVED BY THE CCF BOARD OF DIRECTORS AND THE ASCO BOARD OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7A CCF DOES NOT HAVE MEMBERS. DIRECTORS OF CCF ARE APPOINTED AND SUBJECT TO REMOVAL BY THE BOARD OF DIRECTORS OF ASCO, EXCEPT FOR DIRECTORS SERVING EX-OFFICIO. FORM 990, PART VI, SECTION A, LINE 7B THE BOARD OF DIRECTORS OF CCF MAY VOTE TO AMEND OR REPEAL THE BYLAWS OF CCF, BUT THE BOARD OF DIRECTORS OF ASCO MUST APPROVE AN AMENDMENT OR REPEAL OF THE BYLAWS TO BE EFFECTIVE. CCF MAY NOT AMEND ITS ARTICLES OF INCORPORATION WITHOUT PROVIDING TO ASCO WRITTEN NOTICE OF THE PROPOSED AMENDMENT AT LEAST THIRTY (30) DAYS IN ADVANCE. FORM 990, PART VI, SECTION B, LINE 11B AN ELECTRONIC COPY OF THE CCF FORM 990 WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS BEFORE IT WAS FILED. THE CCF FORM 990 WAS REVIEWED BY THE CHIEF FINANCIAL OFFICER, THE EXECUTIVE VICE PRESIDENT AND CHIEF PHILANTHROPIC OFFICER, THE CEO, AND THE GENERAL COUNSEL PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C CCF MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL CCF STAFF, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G., SPOUSE, DEPENDENT CHILDREN). UNDER CCF'S POLICIES, COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS,CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE, AND UPDATED ANNUALLY THEREAFTER OR WHEN ANY MATERIAL CHANGES OCCUR. CCF'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, WHEN CCF IS CONTEMPLATING ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY "INTERESTED PERSON" (I.E., A CCF DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERNATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINES 15A & 15B THE FOLLOWING EMPLOYEES OF ASCO SERVE AS OFFICERS OF CCF: CEO OF CCF (ALSO SERVES AS CEO OF ASCO) EXECUTIVE VICE PRESIDENT AND CHIEF PHILANTHROPIC OFFICER OF CCF CFO OF CCF INFORMATION REGARDING THEIR COMPENSATION AND THE PROCESS FOR DETERMINING THEIR COMPENSATION ARE DESCRIBED IN THE IRS FORM 990 OF ASCO. CCF STAFF ARE EMPLOYEES OF ASCO WHO ARE LEASED TO CCF. APPLICABLE INFORMATION REGARDING THEIR COMPENSATION IS DESCRIBED IN THE IRS FORM 990 OF ASCO. CCF DOES NOT PAY COMPENSATION TO THESE INDIVIDUALS. FORM 990, PART VI, SECTION C, LINE 19 CCF'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM CCF UPON REQUEST. CCF'S ARTICLES OF INCORPORATION ARE ALSO AVAILABLE TO THE PUBLIC THROUGH THE VIRGINIA STATE CORPORATION COMMISSION. CONFLICT OF INTEREST POLICIES AND STANDARDS ARE POSTED ON CCF'S WEBSITE. THE ANNUAL REPORT OF CCF IS POSTED ON CCF'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM CCF UPON REQUEST. THE AUDITED FINANCIAL STATEMENTS OF CCF ARE POSTED ON CCF'S WEBSITE. AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2318 MILL RD 800 ALEXANDRIA VA 22314 136180380 education NY 501C3 10 false false true true true false false false false false false true true false true true true true false false